QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
May 02 2024 - 8:00AM
Business Wire
Brings More Than Two Decades of Leadership
Experience in the In-Vitro Diagnostics Industry
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or
“QuidelOrtho”), a global provider of innovative in-vitro diagnostic
technologies designed for point of care settings, clinical labs and
transfusion medicine, announced the Company’s Board of Directors
(the “Board”) has appointed Brian J. Blaser as President and Chief
Executive Officer (“CEO”) effective May 6. In addition to his
appointment as President and CEO, Mr. Blaser will join the Board,
effective May 15, 2024, when the Board will be expanded from ten to
eleven members.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240502548327/en/
Brian J. Blaser (Photo: Business
Wire)
“We are excited to welcome Brian as our new president, CEO and
director,” said Kenneth F. Buechler, Ph.D., Chairman of the Board.
“Brian brings over 25 years of senior leadership experience in the
in-vitro diagnostics industry, including seven years of full
responsibility for Abbott’s global diagnostics business. His proven
track record of executing transformational strategies to streamline
operations and driving revenue growth to dramatically improve
profitability makes him an ideal leader to guide QuidelOrtho
through its next phase of growth.”
Mr. Blaser most recently served as Executive Vice President,
Diagnostic Products of Abbott Laboratories, where he oversaw the
global diagnostics organization, including core laboratory, point
of care, rapid diagnostics, and molecular diagnostics businesses.
Prior to that role, Mr. Blaser held various strategic, operational,
and diagnostic roles at Abbott, as well as previous leadership
positions at the Ortho Clinical Diagnostics division of Johnson
& Johnson, Eastman Kodak, and General Motors.
“I am honored and excited to join QuidelOrtho as president and
CEO during this pivotal point in the Company’s journey. The
Company’s commitment to customer service and its dedication to
improving healthcare outcomes align closely with my own values,”
said Brian J. Blaser, President and CEO, QuidelOrtho. “I am eager
to collaborate with the QuidelOrtho team to drive innovation and
continued growth, while delivering value to customers, shareholders
and employees.”
Mr. Blaser holds an MBA with a concentration in Finance from the
Rochester Institute of Technology and a Bachelor of Sciences in
Mechanical Engineering Technology from the University of Dayton. He
is actively involved in various industry and community
organizations, including serving as Advisory Council Chair of the
University of Dayton School of Engineering and Chairman of the
Board of Trustees for Cristo-Rey St. Martin College Prep.
“The Board would also like to take this opportunity to thank
Michael Iskra, Robert Bujarski and Joseph Busky for their
leadership during this transition period. Together, they advanced
many critical initiatives while stabilizing a solid foundation for
the Company’s continued growth,” Dr. Buechler said.
The Company will report its first quarter 2024 financial results
on May 8, 2024.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in
in-vitro diagnostics, developing and manufacturing intelligent
solutions that transform data into understanding and action for
more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular
testing, clinical chemistry, and transfusion medicine, bringing
fast, accurate and reliable diagnostics when and where they are
needed–from home to hospital, lab to clinic. So that patients,
clinicians and health officials can spot trends sooner, respond
quicker and chart the course ahead with accuracy and
confidence.
Building upon its many years of groundbreaking innovation,
QuidelOrtho continues to partner with customers across the
healthcare continuum and around the globe to forge a new diagnostic
frontier. One where insights and solutions know no bounds,
expertise seamlessly connects, and a more informed path is
illuminated for each of us.
QuidelOrtho is advancing diagnostics to power a healthier
future.
For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502548327/en/
Investor Contact: Juliet Cunningham Vice President, Investor
Relations IR@QuidelOrtho.com
Media Contact: D. Nikki Wheeler Senior Director, Corporate
Communications media@QuidelOrtho.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Aug 2023 to Aug 2024